Johnson & Johnson (JNJ)

JNJ (NYSE:Drugs) EQUITY
$102.80
pos +1.59
+1.57%
Today's Range: 101.22 - 103.18 | JNJ Avg Daily Volume: 9,177,100
Last Update: 02/26/15 - 4:03 PM EST
Volume: 11,431,670
YTD Performance: -3.21%
Open: $101.38
Previous Close: $101.21
52 Week Range: $90.75 - $109.49
Oustanding Shares: 2,799,110,362
Market Cap: 281,870,413,453
6-Month Chart
TheStreet Ratings Grade for JNJ
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 5 5 5 5
Moderate Buy 3 3 3 3
Hold 7 7 7 7
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.13 2.13 2.13 2.13
Latest Dividend: 0.70
Latest Dividend Yield: 2.78%
Dividend Ex-Date: 02/20/15
Price Earnings Ratio: 17.67
Price Earnings Comparisons:
JNJ Sector Avg. S&P 500
17.67 17.70 26.88
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-5.15% 11.09% 57.01%
GROWTH 12 Mo 3 Yr CAGR
Revenue 6.10 0.14 0.05
Net Income 18.00 0.69 0.19
EPS 18.50 0.63 0.17
Earnings for JNJ:
EBITDA 21.12B
Revenue 74.33B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $1.52 $1.73 $6.21 $6.50
Number of Analysts 8 7 12 11
High Estimate $1.60 $1.86 $6.30 $6.61
Low Estimate $1.43 $1.50 $6.15 $6.32
Prior Year $1.54 $1.66 $5.97 $6.21
Growth Rate (Year over Year) -1.06% 4.22% 3.94% 4.83%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
But there's just too much good news.
It takes patience not to settle for a lesser idea.
It is no pipedream that the stock could trade to $240.
JNJ provides low-risk, good income and modest appreciation.
Even the best companies reporting can't sustain much lift.
I would look to buy the weakness inside the $102.30-$100.59 zone.
Watch the ECB, economic data, and earnings.
Bearish
Jan 15, 2015 | 7:07 AM EST
JNJ was downgraded from Neutral to Sell, Goldman Sachs said. $97 price target. Company lacks near-term catalysts. 
Watch the share count when looking at earnings.
The next 10 Dow components in my analysis.

Columnist Conversations

I know right JC! It's that zombie that refuses to go away. (the company recently announced the closure of my ...
If you follow the oil markets this is a must read! http://www.platts.com/latest-news/oil/americas/hollyfrontie...
Many of the same 'talking heads' who thought rates would rise in 2014 now believe that rates will decline in 2...
I don't know, Soz, they cant kill this thing but I like your thoughts!

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.